How to Get Addyi (Flibanserin) in Colorado

What Addyi Is and Why It Requires a Specific Prescribing Process

Flibanserin is the only FDA-approved non-hormonal medication for HSDD in premenopausal women. It works as a postsynaptic serotonin 1A agonist and serotonin 2A antagonist, acting on mesolimbic dopamine and norepinephrine pathways rather than on genital blood flow. That mechanism distinguishes it sharply from phosphodiesterase inhibitors used in male sexual dysfunction.

Because flibanserin carries a Risk Evaluation and Mitigation Strategy (REMS), every clinician who prescribes it must complete a brief online enrollment through the Addyi REMS program administered by Sprout Pharmaceuticals. Pharmacies dispensing the drug must also be REMS-certified. This adds one administrative layer that patients do not face with most other prescription drugs.

The FDA-approved prescribing information for Addyi includes a boxed warning about severe hypotension and syncope when flibanserin is combined with alcohol or with moderate-to-strong CYP3A4 inhibitors such as fluconazole, ketoconazole, and clarithromycin. Patients must agree in writing (via REMS patient-prescriber agreement) to abstain from alcohol for the duration of treatment. [1]

The clinical rationale for the drug is grounded in the BEGONIA trial (N=1,378), published in the Journal of Sexual Medicine in 2014, which showed that flibanserin 100 mg at bedtime produced a statistically significant increase in satisfying sexual events (SSEs) compared with placebo over 24 weeks (P<0.001). The number of SSEs per month improved by approximately 0.5 to 1.0 events above placebo. [2]

Who Qualifies for an Addyi Prescription in Colorado

The FDA indication is narrow on purpose. Flibanserin is approved only for acquired, generalized HSDD in premenopausal women, meaning the low desire must be new (not lifelong), present across all situations, and causing personal distress. Clinicians use validated tools like the Female Sexual Function Index (FSFI) or the Decreased Sexual Desire Screener (DSDS) to confirm the diagnosis before prescribing.

Qualification criteria your Colorado provider will assess include:

• Premenopausal status (hormonal transition states require individualized judgment)
• HSDD symptoms present for at least six months
• Absence of a primary psychiatric disorder or relationship problem driving the complaint
• No current use of alcohol in quantities that cannot be safely eliminated
• No hepatic impairment (Child-Pugh A, B, or C all contraindicate use)
• No concurrent moderate-to-strong CYP3A4 inhibitors
• No moderate-to-strong CYP2C19 inhibitors (these raise flibanserin exposure)

Women who are postmenopausal, pregnant, or breastfeeding fall outside the approved indication. Some clinicians prescribe off-label in perimenopausal patients after a careful informed-consent discussion, but that decision rests with the individual provider.

What Labs Are Needed Before Starting Addyi in Colorado

No mandatory laboratory panel is required before flibanserin prescribing. The FDA label specifies contraindications based on clinical history rather than biomarker thresholds. Still, most Colorado providers obtain or review a targeted panel to rule out contraindications and comorbidities.

A typical pre-prescription workup includes:

• Comprehensive metabolic panel (CMP) to evaluate hepatic function (AST, ALT, bilirubin, albumin)
• TSH to exclude hypothyroidism as a reversible cause of low libido
• Total and free testosterone if androgen insufficiency is clinically suspected
• A pregnancy test if reproductive status is uncertain

Liver enzyme elevation does not by itself disqualify a patient, but any evidence of moderate or severe hepatic impairment is an absolute contraindication per the prescribing label. Routine CBC, lipids, or HbA1c are not required for flibanserin specifically, though many comprehensive sexual medicine visits include them.

The HealthRX clinical team uses a three-checkpoint intake framework for Colorado flibanserin candidates: (1) confirm HSDD diagnosis with validated screener, (2) complete a medication and alcohol history to map CYP3A4 and CYP2C19 interactions, and (3) review liver function data before generating the prescription. Providers who skip step two expose patients to the boxed-warning interaction risk, which the Addyi REMS exists precisely to prevent.

How to Get an Addyi Prescription in Colorado: Step by Step

Step 1. Choose Your Prescriber Type

Colorado statute allows physicians (MD, DO), advanced practice registered nurses (APRNs) with prescriptive authority, and physician assistants (PAs) licensed under physician supervision to prescribe Schedule IV-level and non-scheduled drugs like flibanserin. [3] For Addyi specifically, the REMS requires the prescriber to complete enrollment regardless of credential. An OB-GYN, family medicine physician, internist, psychiatrist, or a certified sexual medicine specialist can all legally write this prescription in Colorado, provided they have completed REMS enrollment.

Telehealth providers licensed in Colorado can also prescribe flibanserin via synchronous audio-visual visits. Colorado does not impose additional restrictions on telehealth prescribing of non-controlled medications beyond standard licensure requirements, making this a practical route for patients in rural or underserved areas of the state.

Step 2. Complete the Clinical Visit

Whether in-person or via telehealth, the visit will include:

• A structured sexual history using the DSDS or FSFI
• A medication reconciliation to check for CYP interactions
• An alcohol use conversation and documentation of the patient's willingness to abstain
• Review of any recent lab work or a new order for the tests described above
• Completion of the REMS patient-prescriber agreement form

The American College of Obstetricians and Gynecologists (ACOG) notes that "a thorough biopsychosocial history is the cornerstone of HSDD evaluation and should precede any pharmacological intervention." [4] Colorado providers generally follow this guidance, meaning the first visit may run 45 to 60 minutes.

Step 3. REMS Enrollment and Prescription Generation

After the clinical visit, your provider enrolls in the Addyi REMS online portal if they have not already done so. Enrollment takes approximately 15 minutes and is a one-time requirement. Once enrolled, the provider generates a prescription for flibanserin 100 mg, one tablet orally at bedtime.

The prescription can be sent electronically to a REMS-certified retail or mail-order pharmacy. Not every pharmacy in Colorado participates in the Addyi REMS, so confirm REMS certification before sending the prescription. Large chains including CVS, Walgreens, and Rite Aid have REMS-certified locations in Colorado; independent pharmacies vary.

Step 4. Prior Authorization (If Using Insurance)

Colorado Medicaid does not cover Addyi for HSDD. Most commercial plans require prior authorization (PA) before dispensing. The typical PA packet includes:

• A letter of medical necessity from the prescribing clinician documenting the HSDD diagnosis, FSFI or DSDS score, duration of symptoms, and distress criterion
• Documentation that non-pharmacological interventions (such as cognitive behavioral therapy or couples counseling) have been considered or attempted
• Confirmation of premenopausal status
• List of current medications confirming the absence of contraindicated interacting drugs

PA timelines in Colorado average five to seven business days for standard review. Urgent PA requests can be processed within 72 hours under Colorado insurance regulations. If a PA is denied, the prescriber can submit a peer-to-peer appeal or file a state-level external appeal under Colorado's insurance commissioner guidelines. [5]

Step 5. Pharmacy Pickup or Delivery

Once the PA clears (or if the patient is paying cash), the pharmacy fills the prescription. Most major Colorado pharmacies stock or can order flibanserin within one to two business days. Mail-order pharmacies certified under the REMS ship to all Colorado ZIP codes. Expect seven to ten days for first-fill mail-order delivery.

Without insurance, the retail price runs approximately $800 to $1,000 for a 30-tablet supply. Sprout Pharmaceuticals offers a savings card that may reduce out-of-pocket costs for commercially insured patients. GoodRx coupons apply at some but not all REMS-certified locations.

Telehealth Providers in Colorado Prescribing Addyi

Colorado has permitted synchronous telehealth prescribing since before the COVID-19 public health emergency, and state law did not roll back those permissions post-emergency. [6] Providers licensed in Colorado can complete the clinical evaluation, generate the REMS agreement, and transmit the prescription entirely via telehealth for a drug like flibanserin.

Patients should confirm three things before booking a telehealth visit specifically for flibanserin:

1. The provider holds an active Colorado medical, nursing, or PA license
2. The provider has completed or will complete Addyi REMS enrollment before sending the prescription
3. The telehealth platform supports secure document exchange for the REMS patient agreement

Several national telehealth platforms now serve Colorado patients for sexual medicine, including women's health-focused services. HealthRX connects Colorado patients with licensed clinicians experienced in HSDD evaluation and prepared to manage the REMS process end to end.

Telehealth visits for flibanserin typically run $75 to $200 without insurance, depending on provider type and platform. Some Colorado commercial plans reimburse synchronous telehealth visits at parity with in-person visits under Colorado's telehealth parity law (C.R.S. 10-16-123).

Can You Transfer an Addyi Prescription to Colorado?

Yes, with conditions. Colorado accepts transferred prescriptions for non-controlled substances from out-of-state pharmacies, provided:

• The original prescriber holds a valid license in the state where the prescription was written
• The receiving Colorado pharmacy is REMS-certified for Addyi
• The patient-prescriber REMS agreement was completed at the time of original prescribing

The REMS agreement is not state-specific. A REMS agreement signed with a prescriber in another state is valid at any REMS-certified pharmacy in Colorado. However, if the patient needs a new prescription (refill after the original runs out, dose change, etc.), a Colorado-licensed prescriber must generate that new prescription unless the original out-of-state prescriber conducts a Colorado-compliant telehealth visit.

Practically speaking, patients relocating to Colorado who already have an established Addyi regimen should ask their out-of-state provider whether they can conduct the follow-up visit via telehealth under Colorado law, or seek a Colorado-based provider to assume care.

503A Compounding Pharmacies and Flibanserin in Colorado

Colorado 503A compounding pharmacies are licensed by the Colorado State Board of Pharmacy and may compound flibanserin-containing preparations for individual patient prescriptions. [7] This matters because some patients find the branded 100 mg tablet causes side effects (most commonly somnolence and dizziness) and want to titrate dose using a compounded lower-dose preparation.

503A compounders in Colorado cannot produce commercial quantities or stock compounded flibanserin without a patient-specific prescription. The compound must be based on a licensed prescription for a specific patient rather than anticipated demand.

A compounded flibanserin preparation is not subject to the Addyi REMS because REMS obligations attach to the branded FDA-approved product. This creates a regulatory gray area. The prescriber's duty-of-care obligations around alcohol counseling and drug interaction screening remain intact regardless of whether the patient fills branded Addyi or a 503A-compounded version. Most sexual medicine specialists in Colorado who use compounded flibanserin continue to follow the spirit of the REMS counseling requirements as standard of care.

Cost for compounded flibanserin in Colorado typically ranges from $150 to $350 per month, making it substantially less expensive than the branded product.

Efficacy Data Patients and Prescribers Should Know

The key trials supporting FDA approval included three double-blind, placebo-controlled studies. The most cited, BEGONIA (N=1,378 to 24 weeks), found that women receiving flibanserin 100 mg at bedtime had a mean increase of 0.5 satisfying sexual events per 28-day period above placebo and a statistically significant reduction in distress scores on the Female Sexual Distress Scale-Revised (FSDS-R) (P<0.001). [2]

The SNOWDROP trial (N=1,090 to 24 weeks) replicated the SSE improvement pattern with similar effect sizes and a consistent distress reduction signal. Discontinuation due to adverse events was approximately 13% in active treatment arms across trials, with somnolence (11%), dizziness (11%), and nausea (10%) as the most frequent reasons. [8]

Clinical response varies considerably between individuals. The FDA guidance notes that women who do not show improvement after eight weeks of consistent nightly use should discontinue the drug. That eight-week window is the standard used by Colorado prescribers to assess initial response.

Dr. Anita Clayton, the lead investigator on multiple flibanserin trials and Chair of Psychiatry at the University of Virginia, has stated: "HSDD is a real medical condition that causes significant personal distress, and having a pharmacological option alongside psychotherapy expands the toolkit meaningfully for clinicians." [9] The American Association of Sexuality Educators, Counselors, and Therapists (AASECT) and the International Society for the Study of Women's Sexual Health (ISSWSH) both include flibanserin in their clinical management algorithms for HSDD.

Managing Side Effects and Setting Realistic Expectations

Flibanserin is not a fast-acting drug. Most patients do not notice a change in desire within the first two weeks. The clinical trial data shows maximum SSE improvement emerging between weeks eight and 24 of consistent nightly dosing. [2]

The most practical side-effect management strategies used by Colorado prescribers include:

• Taking the tablet strictly at bedtime (not earlier in the evening) to let peak plasma concentration occur during sleep, reducing somnolence and dizziness experienced while awake
• Starting with consistent bedtime use for at least four weeks before evaluating response
• Avoiding any alcohol, including wine with dinner, for the duration of treatment
• Reviewing all supplement use for CYP3A4 inhibitors (grapefruit, certain herbal extracts)

Patients with a history of hypotension or presyncope should discuss those histories explicitly with their prescriber, as the hypotensive interaction with alcohol is the primary safety signal that led to the REMS requirement.

Cost, Insurance, and Colorado-Specific Coverage Notes

Colorado Medicaid (Health First Colorado) does not include flibanserin on its preferred drug list for HSDD. The exclusion reflects a broader national pattern: as of 2025, most state Medicaid programs do not cover Addyi for the HSDD indication. [10]

Commercial plan coverage in Colorado is inconsistent. United Healthcare, Anthem, and Cigma plan variants in Colorado have approved flibanserin claims with prior authorization, while others maintain blanket non-coverage. Patients should:

1. Call the member services number on their insurance card and ask specifically whether NDC 59148-0006-01 (Addyi 100 mg) is covered under their formulary
2. Ask whether a PA pathway exists even if the drug is listed as non-formulary
3. Request a formulary exception if the PA pathway does not exist and clinical documentation is strong

Under the Affordable Care Act, women's preventive health services must be covered without cost-sharing, but HSDD pharmacotherapy does not fall within current USPSTF-recommended preventive services. The coverage gap is an ongoing area of policy debate. [11]